- Home
- BFRI
BFRI
Biofrontera Inc.
as 11-21-2024 4:00pm EST
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | WOBURN |
| Market Cap: | 6.2M | IPO Year: | 2021 |
| Target Price: | $7.00 | AVG Volume (30 days): | 7.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $4.04 | Next Earning Date: | 11-13-2024 |
| Revenue: | $35,358,000 | Revenue Growth: | 5.17% |
| Revenue Growth (this year): | 19.11% | Revenue Growth (next year): | 20.16% |
Latest Biofrontera Inc. News
BFRI Breaking Stock News: Dive into BFRI Ticker-Specific Updates for Smart Investing
GuruFocus.com
7 days ago
Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...
Zacks
8 days ago
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
8 days ago
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
ACCESSWIRE
20 days ago
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
GlobeNewswire
21 days ago
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
GuruFocus.com
a month ago
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc
GlobeNewswire
a month ago
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
GuruFocus.com
a month ago
Biofrontera Inc (BFRI) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Compare BFRI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BFRI Biofrontera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.